SCHEMBL18323633

SCHEMBL18323633

Cc1nnc2cc(C(N)=O)cc(OCCO)n12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.38
IKBKB O14920 1/20 0.34
CHEK2 O96017 3/20 0.33
KDM4E B2RXH2 2/20 0.33
TSHR P16473 1/20 0.33
LMNA P02545 2/20 0.33
BPTF Q12830 1/20 0.32
KMT2A Q03164 2/20 0.31
MKNK2 Q9HBH9 2/20 0.31
MKNK1 Q9BUB5 1/20 0.31
ALDH1A1 P00352 2/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
MEN1 O00255 1/20 0.30
PARP10 Q53GL7 1/20 0.30
HTT P42858 1/20 0.30
POLB P06746 1/20 0.30
MAPT P10636 1/20 0.30
HPGD P15428 1/20 0.30
AHR P35869 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18323581 0.88 KDM4E (0.34) BRD4KDM4EKMT2AALDH1A1MEN1
SCHEMBL18323621 0.86 TSHR (0.44) BRD4CHEK2KDM4ETSHRLMNA
SCHEMBL18323590 0.86 KDM4E (0.39) KDM4ELMNAKMT2AALDH1A1SMN1; SMN2
SCHEMBL15907098 0.84 CHEK2 (0.32) IKBKBCHEK2TSHRKMT2AMEN1
SCHEMBL18323620 0.82 BRD4 (0.39) BRD4KDM4ETSHRLMNABPTF
SCHEMBL18323638 0.80 KDM4E (0.50) BRD4KDM4EKMT2A
SCHEMBL18323618 0.75 KDM4E (0.55) BRD4KDM4ETSHRLMNAKMT2A
SCHEMBL18323675 0.73 BRD4 (0.39) BRD4KDM4ETSHRLMNABPTF
SCHEMBL18323639 0.73 BRD4 (0.40) BRD4KDM4ELMNAKMT2AMKNK2
SCHEMBL18323673 0.72 TSHR (0.43) CHEK2KDM4ETSHRLMNABPTF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 US disclosed